Welcome to the Penn Pancreatic Cancer Research Center!
The Penn Pancreatic Cancer Research Center (PCRC) is committed to delivering high-quality care for patients with pancreatic cancer. We take a multidisciplinary approach — integrating Medical Oncology, Surgery, Gastroenterology, Radiation Oncology, and Pathology — to deliver comprehensive and personalized options to our patients.
The American Cancer Society has reported that in 2018 pancreatic cancer became the third leading cause of cancer death in the U.S., surpassing breast cancer (for more, see Cancer Statistics). One encouraging piece of this report is that the five-year relative survival rate for pancreatic cancer has moved to 10* percent (from 5 percent several years ago). At the Penn Pancreatic Cancer Research Center (PCRC), we understand the urgent need to develop better treatments and cures for patients.
News
PCRC researchers and clinicians gathered with patients, survivors, and caregivers at the 2024 PanCAN Purplestride (Premier Sponsor – Penn Medicine's Abramson Cancer Center) in the annual walk/run to END PANCREATIC CANCER.
Our team (Penn Pancreatic Cancer Research Center) was #2 in fundraising for this event!
- Follow us on Facebook
|
|
PurpleStride event in Philly raises money for those battling pancreatic cancer This weekend people will come together for PurpleStride, an event in Philly that raises money for research and awareness in the fight against pancreatic cancer. NBC10's Brian Sheehan spoke with a longtime cancer survivor who will be in the crowd offering hope for those battling the disease. |
Kevin Edmonds and "A Love for Life" Fund at Penn Presbyterian Oncology:
Research Advances
Results from the phase 1b study of CD40 agonists with or without PD-1 inhibition for the treatment of metastatic pancreatic cancer reported in Lancet Oncology. View our publication at Pubmed.
For more of our published research, see the Publications page.
Information for Clinical Trials
We believe in the power of clinical trials in caring for patients and conquering this disease.
View more information on clinical trials.